Literature DB >> 34956503

Analysis of risk factors for early clinical recurrence of inflammatory bowel disease after fecal microbiota transplantation.

Di Zhao1,2, Chen Ye1,2, Shaoyi Zhang1,2, Xiaoqiong Lv1,2, Bo Yang1,2.   

Abstract

OBJECTIVE: To explore the risk factors for early clinical recurrence of inflammatory bowel disease (IBD) after fecal microbiota transplantation (FMT).
METHODS: A retrospective study was conducted on 192 patients with IBD who received FMT treatment in the Colorectal Disease Specialty/Intestinal Microecology Treatment Center of the Tenth People's Hospital Affiliated to Tongji University from February 2017 to June 2020. Univariate and multivariate logistic regression models were used to analyze the risk factors for early recurrence of inflammation. Feces from all participants were collected to extract the total bacterial genomic DNA. The V6-8 regions of the bacterial 16S rDNA gene were amplified by polymerase chain reaction (PCR), the PCR products were detected by the denaturing gradient gel electrophoresis (DGGE) method, and the intestinal flora was analyzed by DNA fingerprinting. Stool samples from all patients were tested for 9 bacteria, white blood cells (WBC) and platelet (PLT) counts, as well as the erythrocyte sedimentation rate (ESR) and serum C-reactive protein (CRP) level.
RESULTS: Of the 192 patients, 15 cases had inflammation recurrence during FMT and within one week after treatment, including 11 cases of ulcerative colitis (UC) and 4 cases of Crohn's disease (CD), with a total recurrence rate of 7.8%. High Mayo inflammatory activity score, Mayo endoscopic sub-item score (MES) =3 points, CRP>10 mg/L, anemia, albumin <30 g/L, absolute value of peripheral blood lymphocytes (PBL) <500/mm3, and intolerance to enteral full nutrition were independent risk factors for recurrence during and after FMT in UC patients (P<0.05). Albumin <30 g/L and simultaneous use of immunosuppressive agents were associated with disease recurrence during and after FMT in CD patients. WBC, PLT, and CRP were all negatively correlated with Enterococcus (EC), and ESR was positively correlated with Saccharomyces boulardii (SB) (P<0.01).
CONCLUSION: The low recurrence rate of IBD after FMT indicates the safety of FMT, but this procedure should be cautiously used in patients with severe intestinal barrier dysfunction and/or severe intestinal dysfunction. AJTR
Copyright © 2021.

Entities:  

Keywords:  Fecal microbiota transplantation; inflammation recurrence; inflammatory bowel disease; risk factors

Year:  2021        PMID: 34956503      PMCID: PMC8661179     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  18 in total

1.  Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis.

Authors:  Udayakumar Navaneethan; Saurabh Mukewar; Preethi G K Venkatesh; Rocio Lopez; Bo Shen
Journal:  J Crohns Colitis       Date:  2011-10-22       Impact factor: 9.071

Review 2.  Host-microbiota interactions in inflammatory bowel disease.

Authors:  Roberta Caruso; Bernard C Lo; Gabriel Núñez
Journal:  Nat Rev Immunol       Date:  2020-01-31       Impact factor: 53.106

Review 3.  The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis.

Authors:  Taha Qazi; Thelina Amaratunga; Edward L Barnes; Monika Fischer; Zain Kassam; Jessica R Allegretti
Journal:  Gut Microbes       Date:  2017-09-12

Review 4.  Role of fecal microbiota transplantation in inflammatory bowel disease.

Authors:  Irene D'Odorico; Stefano Di Bella; Jacopo Monticelli; Daniele R Giacobbe; Emma Boldock; Roberto Luzzati
Journal:  J Dig Dis       Date:  2018-05-29       Impact factor: 2.325

5.  Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.

Authors:  Konrad Aden; Ateequr Rehman; Silvio Waschina; Wei-Hung Pan; Alesia Walker; Marianna Lucio; Alejandro Mena Nunez; Richa Bharti; Johannes Zimmerman; Johannes Bethge; Berenice Schulte; Dominik Schulte; Andre Franke; Susanna Nikolaus; Johann Oltmann Schroeder; Doris Vandeputte; Jeroen Raes; Silke Szymczak; Georg H Waetzig; Rainald Zeuner; Philippe Schmitt-Kopplin; Christoph Kaleta; Stefan Schreiber; Philip Rosenstiel
Journal:  Gastroenterology       Date:  2019-07-18       Impact factor: 22.682

6.  Fecal transplant is as effective and safe in immunocompromised as non-immunocompromised patients for Clostridium difficile.

Authors:  Amar Mandalia; Angela Ward; William Tauxe; Colleen S Kraft; Tanvi Dhere
Journal:  Int J Colorectal Dis       Date:  2015-09-26       Impact factor: 2.571

7.  Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.

Authors:  Gaik W Tew; Jason A Hackney; Deena Gibbons; Christopher A Lamb; Diana Luca; Jackson G Egen; Lauri Diehl; Jeff Eastham Anderson; Severine Vermeire; John C Mansfield; Brian G Feagan; Julian Panes; Daniel C Baumgart; Stefan Schreiber; Iris Dotan; William J Sandborn; John A Kirby; Peter M Irving; Gert De Hertogh; Gert A Van Assche; Paul Rutgeerts; Sharon O'Byrne; Adrian Hayday; Mary E Keir
Journal:  Gastroenterology       Date:  2015-10-30       Impact factor: 22.682

8.  Peripheral Lymphocytes of Patients with Inflammatory Bowel Disease Have Altered Concentrations of Key Apoptosis Players: Preliminary Results.

Authors:  Katarzyna Neubauer; Barbara Woźniak-Stolarska; Małgorzata Krzystek-Korpacka
Journal:  Biomed Res Int       Date:  2018-11-01       Impact factor: 3.411

Review 9.  The Super-Donor Phenomenon in Fecal Microbiota Transplantation.

Authors:  Brooke C Wilson; Tommi Vatanen; Wayne S Cutfield; Justin M O'Sullivan
Journal:  Front Cell Infect Microbiol       Date:  2019-01-21       Impact factor: 5.293

10.  Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study.

Authors:  Harry Sokol; Cecilia Landman; Philippe Seksik; Laurence Berard; Mélissa Montil; Isabelle Nion-Larmurier; Anne Bourrier; Guillaume Le Gall; Valérie Lalande; Alexis De Rougemont; Julien Kirchgesner; Anne Daguenel; Marine Cachanado; Alexandra Rousseau; Élodie Drouet; Michelle Rosenzwajg; Hervé Hagege; Xavier Dray; David Klatzman; Philippe Marteau; Laurent Beaugerie; Tabassome Simon
Journal:  Microbiome       Date:  2020-02-03       Impact factor: 14.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.